Xolair

Honeybees on honeycomb in hive
Biotech

Novartis hands over $55M to license preclinical hives prospect

Novartis is paying Kyorin $55 million upfront for rights to a preclinical mast-cell-targeting candidate for chronic hives.
Darren Incorvaia Mar 3, 2025 5:05pm
compass map direction find trail north

Rapt pays $35M for challenger to Novartis, Roche drug

Dec 23, 2024 8:10am
soccer kick off ball football field play game crowd boots cleats

Celldex laces up next to Big Pharmas with chronic hive drug

Nov 6, 2023 10:17am